Investigation of factors which are related to urinary volume change after canagliflozin administration - Investigation of factors which are related to urinary volume change after canagliflozin administration

Medical Corporation Hokubukai Utsukushigaoka Hospital, Clinical Pharmacology Center0 sites12 target enrollmentOctober 26, 2015

Overview

Phase: 未知
Intervention: Not specified
Conditions: Type2 diabetes mellitus
Sponsor: Medical Corporation Hokubukai Utsukushigaoka Hospital, Clinical Pharmacology Center
Enrollment: 12
Status: Completed
Last Updated: 2 years ago

No summary available.

Registry

who.int

Start Date

October 26, 2015

End Date

December 15, 2015

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

Medical Corporation Hokubukai Utsukushigaoka Hospital, Clinical Pharmacology Center

•1\. Patients who have not received treatment of type 2 diabetes mellitus(diet therapy, exercise therapy, oral hypoglycemic agent and so on) 2\. Patient with type 1 diabetes mellitus or with history of secondary diabetes mellitus 3\. Patients who have experienced repeated severe hypoglycemic episodes 4\. Patients with the history of serious diabetic complications requiring treatment 5\. Patients treated with insulin, GLP\-1 receptor agonist, SGLT\-2 inhibitor, diuretic (including drug combination) 6\. Patients with history of , or concurrent complication that affect renal function(renal disease, renal stone, prostatic inflammation and so on) , or patients with urinary\-tract infection 7\. Patients with history of drug or food allergies 8\. Patients with history of myocardial infarction, congestive heart failure, unstable angina, cerebrovascular disease(except for lacunar infarction)within 6 months prior to screening visit (confirmation of eligibility) 9\. Patients with history of TIA or cerebral infarction with clear neurological symptoms 10\. Patients with peripheral arterial disease; Fontaine grade 3 or 4 11\. Patients who correspond to contraindication or careful administration of canagliflozin (except for patient under treatment of hypoglycemic agents) 12\. Patients with history of atrial fibrillation 13\. Patients who are judged as inappropriate by investigators on screening examination.